CA2389236A1 — Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
Assigned to Assertio Holdings Inc · Expires 2001-05-10 · 25y expired
What this patent protects
Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of variou s substances that have been discovered to function as potent agents for induci ng the fed mode. By inducing the onset of the fed…
USPTO Abstract
Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of variou s substances that have been discovered to function as potent agents for induci ng the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is eithe r large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, .szlig.- casomorphins, a-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4' - aryl-4'-hydroxypiperidino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.